Regeneron’s COVID-19 cocktail helps prevent symptomatic disease, results suggest

On Apr 12, 2021

Regeneron’s COVID-19 antibody cocktail has helped reduce the risk of symptomatic infections by 81% among people in households where another member had become ill.

This was according to a statement released on Monday by Regeneron’s manufacturing partner, Roche.

“In addition, individuals treated with casirivimab and imdevimab who still experienced a symptomatic infection resolved their symptoms on average within one week, compared to three weeks with placebo,” the company said.

MTO/Reuters